DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: VOX
Drug: SOF/VEL

First Posted Date: 2015-03-04

Last Posted Date: 2020-03-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 128

Registration Number: NCT02378961

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Borland-Groover Clinic, Jacksonville, Florida, United States

and more 31 locations

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: VOX
Drug: SOF/VEL
Drug: RBV

First Posted Date: 2015-03-04

Last Posted Date: 2020-03-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 205

Registration Number: NCT02378935

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Southwest Care Center, Santa Fe, New Mexico, United States

and more 31 locations

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Phase 2

Withdrawn

Conditions: Ischemic Heart Disease

Interventions: Drug: GS-6615
Drug: Placebo

First Posted Date: 2015-03-03

Last Posted Date: 2015-06-08

Lead Sponsor: Gilead Sciences

Registration Number: NCT02377336

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Phase 1

Completed

Conditions: Long QT Syndrome

Interventions: Drug: Placebo to match GS-6615
Drug: GS-6615
Drug: Placebo to match dofetilide
Drug: Dofetilide

First Posted Date: 2015-02-19

Last Posted Date: 2015-05-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 60

Registration Number: NCT02365532

Locations: 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

Phase 1

Completed

Conditions: LQT2 Syndrome

Interventions: Drug: Eleclazine
Drug: Placebo

First Posted Date: 2015-02-19

Last Posted Date: 2020-12-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 13

Registration Number: NCT02365506

Locations: 🇺🇸
University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF

First Posted Date: 2015-01-29

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 17

Registration Number: NCT02350569

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2015-01-27

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 111

Registration Number: NCT02346721

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: FTC/RPV/TDF
Drug: FTC/RPV/TAF
Drug: FTC/RPV/TDF Placebo
Drug: FTC/RPV/TAF Placebo

First Posted Date: 2015-01-26

Last Posted Date: 2020-01-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 632

Registration Number: NCT02345252

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada
🇺🇸
AHF Research Center, Beverly Hills, California, United States
🇺🇸
Pacific Oaks Medical Group, Beverly Hills, California, United States

and more 110 locations

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: FTC/RPV/TAF
Drug: EFV/FTC/TDF
Drug: EFV/FTC/TDF Placebo
Drug: FTC/RPV/TAF Placebo

First Posted Date: 2015-01-26

Last Posted Date: 2020-01-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 881

Registration Number: NCT02345226

Locations: 🇺🇸
Brigham and Women's, Boston, Massachusetts, United States
🇺🇸
Southern California Men's Medical Group, Los Angeles, California, United States
🇺🇸
Tarrant County ID Associates, Los Angeles, California, United States

and more 110 locations

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Entospletinib
Drug: Daunorubicin
Drug: Decitabine
Drug: Cytarabine
Drug: Azacitidine

First Posted Date: 2015-01-22

Last Posted Date: 2019-11-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 148

Registration Number: NCT02343939

Locations: 🇺🇸
University of Kansas Medical Center Research Institute, Inc, Fairway, Kansas, United States
🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇺🇸
Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy